{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T00:52:43Z","timestamp":1794185563943,"version":"4.8.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.ajo.2025.04.022","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T18:56:55Z","timestamp":1745607415000},"page":"252-260","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Ocular Adverse Events Associated with Pegcetacoplan and Avacincaptad Pegol for Geographic Atrophy: A Population-Based Pharmacovigilance Study"],"prefix":"10.1016","volume":"276","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-6750-2733","authenticated-orcid":false,"given":"Zeena","family":"Kailani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Mihalache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0370-5968","authenticated-orcid":false,"given":"Marko M.","family":"Popovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Kertes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0465-6472","authenticated-orcid":false,"given":"Rajeev H.","family":"Muni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajo.2025.04.022_bib0001","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/aos.15767","article-title":"Epidemiology of geographic atrophy and its precursor features of intermediate age-related macular degeneration","volume":"101","author":"Vujosevic","year":"2023","journal-title":"Acta Ophthalmol"},{"issue":"16","key":"10.1016\/j.ajo.2025.04.022_bib0002","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.3390\/cells12162092","article-title":"The role of inflammation in age-related macular degeneration\u2014therapeutic landscapes in geographic atrophy","volume":"12","author":"Borchert","year":"2023","journal-title":"Cells"},{"issue":"5-A Suppl","key":"10.1016\/j.ajo.2025.04.022_bib0003","first-page":"S2","article-title":"Geographic atrophy: mechanism of disease, pathophysiology, and role of the complement system","volume":"29","author":"Bakri","year":"2023","journal-title":"J Manag Care Spec Pharm"},{"issue":"3","key":"10.1016\/j.ajo.2025.04.022_bib0004","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/ICU.0000000000001046","article-title":"Geographic atrophy: current and future therapeutic agents and practical considerations for retinal specialists","volume":"35","author":"Vakharia","year":"2024","journal-title":"Curr Opin Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2025.04.022_bib0005","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3928\/23258160-20230106-01","article-title":"Complement inhibitors for the treatment of geographic atrophy","volume":"54","author":"Amin","year":"2023","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"12","key":"10.1016\/j.ajo.2025.04.022_bib0006","doi-asserted-by":"crossref","first-page":"682","DOI":"10.3928\/23258160-20231031-01","article-title":"Advances in imaging techniques for geographic atrophy","volume":"54","author":"Tan","year":"2023","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.ajo.2025.04.022_bib0007","article-title":"APL-2, a complement C3 inhibitor, slows the growth of geographic atrophy secondary to AMD: 18-month results of a phase 2 trial (FILLY)","volume":"59","author":"Wykoff","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"12","key":"10.1016\/j.ajo.2025.04.022_bib0008","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1080\/1750743X.2024.2368342","article-title":"C5 inhibitor avacincaptad pegol treatment for geographic atrophy: a comprehensive review","volume":"16","author":"Danzig","year":"2024","journal-title":"Immunotherapy"},{"issue":"10411","key":"10.1016\/j.ajo.2025.04.022_bib0009","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/S0140-6736(23)01520-9","article-title":"Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials","volume":"402","author":"Heier","year":"2023","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ajo.2025.04.022_bib0010","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.ophtha.2020.08.027","article-title":"C5 inhibitor avacincaptad pegol for geographic atrophy due to age-related macular degeneration: a randomized pivotal phase 2\/3 trial","volume":"128","author":"Jaffe","year":"2021","journal-title":"Ophthalmology"},{"issue":"10411","key":"10.1016\/j.ajo.2025.04.022_bib0011","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S0140-6736(23)01583-0","article-title":"Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial","volume":"402","author":"Khanani","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ajo.2025.04.022_bib0012","unstructured":"Center for Drug Evaluation and Research. FDA Adverse Event Reporting System (FAERS) public dashboard. US Food and Drug Administration. https:\/\/www.fda.gov\/drugs\/fdas-adverse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-public-dashboard"},{"key":"10.1016\/j.ajo.2025.04.022_bib0013","author":"B\u00f6hm"},{"issue":"6","key":"10.1016\/j.ajo.2025.04.022_bib0014","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"10.1016\/j.ajo.2025.04.022_bib0015","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s40264-020-00911-w","article-title":"Disproportionality analysis for pharmacovigilance signal detection in small databases or subsets: recommendations for limiting false-positive associations","volume":"43","author":"Caster","year":"2020","journal-title":"Drug Saf"},{"key":"10.1016\/j.ajo.2025.04.022_bib0016","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1038\/s41433-023-02497-w","article-title":"Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial","volume":"37","author":"Patel","year":"2023","journal-title":"Eye"},{"key":"10.1016\/j.ajo.2025.04.022_bib0017","unstructured":"SYFOVRE\u2122 (pegcetacoplan injection), for intravitreal use. Package insert. US Food and Drug Administration website. Accessed February 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/217171s001lbl.pdf."},{"issue":"1","key":"10.1016\/j.ajo.2025.04.022_bib0018","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1177\/24741264231220224","article-title":"Retinal vasculitis after intravitreal pegcetacoplan: report from the ASRS Research and Safety in Therapeutics (ReST) Committee","volume":"8","author":"Witkin","year":"2023","journal-title":"J Vitreoretin Dis"},{"issue":"3","key":"10.1016\/j.ajo.2025.04.022_bib0019","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3928\/23258160-20241216-01","article-title":"Favorable outcome after pegcetacoplan (Syfovre)-associated occlusive retinal vasculitis","volume":"56","author":"Leung","year":"2025","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.ajo.2025.04.022_bib0020","unstructured":"IZERVAY\u2122 (avacincaptad pegol intravitreal solution). Label. US Food and Drug Administration website. Accessed August 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/217225s000lbl.pdf"},{"key":"10.1016\/j.ajo.2025.04.022_bib0021","unstructured":"Apellis Pharmaceuticals, Inc. Apellis pharmaceuticals reports fourth quarter and full year 2024 financial results. Accessed April 6, 2025. https:\/\/investors.apellis.com\/news-releases\/news-release-details\/apellis-pharmaceuticals-reports-fourth-quarter-and-full-year-6"},{"key":"10.1016\/j.ajo.2025.04.022_bib0022","unstructured":"Astellas Pharma Inc. U.S. FDA approves expanded label for Astellas\u2019 IZERVAY\u2122 (avacincaptad pegol intravitreal solution) for geographic atrophy. Published February 12, 2025. Accessed April 6, 2025. https:\/\/www.prnewswire.com\/news-releases\/us-fda-approves-expanded-label-for-astellas-izervay-avacincaptad-pegol-intravitreal-solution-for-geographic-atrophy-302375403.html"},{"issue":"18","key":"10.1016\/j.ajo.2025.04.022_bib0023","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s40265-022-01809-w","article-title":"Pegcetacoplan: a review in paroxysmal nocturnal haemoglobinuria","volume":"82","author":"Heo","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.ajo.2025.04.022_bib0024","unstructured":"Medscape. Novel drug shows benefits in rare C3G and primary immune complex MPGN, with high safety margin. Published December 5, 2024. https:\/\/www.medscape.com\/"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939425001990?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939425001990?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T08:56:11Z","timestamp":1751964971000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939425001990"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":24,"alternative-id":["S0002939425001990"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2025.04.022","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ocular Adverse Events Associated with Pegcetacoplan and Avacincaptad Pegol for Geographic Atrophy: A Population-Based Pharmacovigilance Study","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2025.04.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}